COMBINED TREATMENT WITH A NEW BISCARBODITHIOATE C9G2DTC AND BGDTC FORMOBILIZING CADMIUM DEPOSITS IN RATS

The cadmium mobilizing efficiency of a combined treatment with a novel cadmium chelating agent disodium glucosyl)-1,9-nonanediamine-N,N'-bis carbodithioate (C9G2DTC) and with sodium N-benzyl-D-glucamine-N-carbod ithioate (BGDTC) was evaluated in albino rats. They received Cd-109 in traperitoneally once and 1 week later chelation therapy six times over 12 days at 2-day intervals. The treatment groups were: 1, control; 2, BGDTC six times; 3, C9G2DTC six times; 4, C9G2DTC three times followe d by BGDTC three times; 5, C9G2DTC twice followed by BGDTC four times; 6, C9G2DTC once followed by BGDTC five times. The radioactivity in li ver, kidney and brain was determined 19 days after Cd-109 administrati on. Results were expressed as a percentage of the Cd-109 dose and diff erences were analyzed by Duncan's multiple range test (P < 0.05). Trea tment with C9G2DTC resulted in higher Cd reduction in the liver and lo wer in the kidney than with BGDTC, which is in agreement with our prev ious findings. Combined treatment resulted in a greater reduction of C d in the liver and kidney than by using either chelating agent alone, irrespective of the number of C9G2DTC or BGDTC treatments; and without causing redistribution to the brain. The important aspect of this wor k is that C9G2DTC-the novel cadmium chelating agent which is extremely efficient in reducing Cd liver deposits and about three times more to xic than BGDTC-has to be used only once at the beginning of the treatm ent to obtain optimal reduction of aged organ cadmium deposits.